Abstract
Ovarian cancer is a highly deadly malignancy in which recurrence is considered incurable. Resistance to platinum-based chemotherapy bodes a particularly abysmal prognosis, underscoring the need for novel therapeutic agents and strategies. The use of mithramycin, an antineoplastic antibiotic, has been previously limited by its narrow therapeutic window. Recent advances in semisynthetic methods have led to mithramycin analogs with improved pharmacological profiles. Mithramycin inhibits the activity of the transcription factor Sp1, which is closely linked with ovarian tumorigenesis and platinum-resistance. This article summarizes recent clinical developments related to mithramycin and postulates a role for the use of mithramycin, or its analog, in the treatment of platinum-resistant ovarian cancer.
| Original language | English |
|---|---|
| Article number | 70 |
| Pages (from-to) | 1-11 |
| Number of pages | 11 |
| Journal | Biomedicines |
| Volume | 9 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2021 |
Bibliographical note
Publisher Copyright:© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Funding
Funding: This research was funded by a NIH Training Grant, T32CA160003, the 2020 Inter-Departmental Collaboration (IDC) Award from the University of Kentucky College of Pharmacy, and by the University of Kentucky Markey Cancer Center (P30 CA177558)
| Funders | Funder number |
|---|---|
| University of Kentucky College of Pharmacy | |
| National Institutes of Health (NIH) | T32CA160003 |
| University of Kentucky Markey Comprehensive Cancer Center | P30 CA177558 |
Keywords
- Mithramycin
- Novel therapeutics
- Ovarian cancer
- Platinum-resistant
- Sp1
ASJC Scopus subject areas
- Medicine (miscellaneous)
- General Biochemistry, Genetics and Molecular Biology
